Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients
While cell‐free liquid biopsy (cfLB) approaches provide simple and inexpensive disease monitoring, cell‐based liquid biopsy (cLB) may enable additional molecular genetic assessment of systemic disease heterogeneity and preclinical model development. We investigated 71 blood samples of 62 patients wi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13741 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850085376996147200 |
|---|---|
| author | Nataša Stojanović Gužvić Florian Lüke Steffi Treitschke Andrea Coluccio Martin Hoffmann Giancarlo Feliciello Adithi Ravikumar Varadarajan Xin Lu Kathrin Weidele Catherine Botteron Silvia Materna–Reichelt Felix Keil Katja Evert Florian Weber Thomas Schamberger Michael Althammer Jirka Grosse Dirk Hellwig Christian Schulz Stephan Seitz Peter Ugocsai Anke Schlenska‐Lange Roman Mayr Ulrich Kaiser Wolfgang Dietmaier Bernhard Polzer Jens Warfsmann Kamran Honarnejad Tobias Pukrop Daniel Heudobler Christoph A. Klein Christian Werno |
| author_facet | Nataša Stojanović Gužvić Florian Lüke Steffi Treitschke Andrea Coluccio Martin Hoffmann Giancarlo Feliciello Adithi Ravikumar Varadarajan Xin Lu Kathrin Weidele Catherine Botteron Silvia Materna–Reichelt Felix Keil Katja Evert Florian Weber Thomas Schamberger Michael Althammer Jirka Grosse Dirk Hellwig Christian Schulz Stephan Seitz Peter Ugocsai Anke Schlenska‐Lange Roman Mayr Ulrich Kaiser Wolfgang Dietmaier Bernhard Polzer Jens Warfsmann Kamran Honarnejad Tobias Pukrop Daniel Heudobler Christoph A. Klein Christian Werno |
| author_sort | Nataša Stojanović Gužvić |
| collection | DOAJ |
| description | While cell‐free liquid biopsy (cfLB) approaches provide simple and inexpensive disease monitoring, cell‐based liquid biopsy (cLB) may enable additional molecular genetic assessment of systemic disease heterogeneity and preclinical model development. We investigated 71 blood samples of 62 patients with various advanced cancer types and subjected enriched circulating tumor cells (CTCs) to organoid culture conditions. CTC‐derived tumoroid models were characterized by DNA/RNA sequencing and immunohistochemistry, as well as functional drug testing. Results were linked to molecular features of primary tumors, metastases, and CTCs; CTC enumeration was linked to disease progression. Of 52 samples with positive CTC counts (≥1) from eight different cancer types, only CTCs from two salivary gland cancer (SGC) patients formed tumoroid cultures (P = 0.0005). Longitudinal CTC enumeration of one SGC patient closely reflected disease progression during treatment and revealed metastatic relapse earlier than clinical imaging. Multiomics analysis and functional in vitro drug testing identified potential resistance mechanisms and drug vulnerabilities. We conclude that cLB might add a functional dimension (to the genetic approaches) in the personalized management of rare, difficult‐to‐treat cancers such as SGC. |
| format | Article |
| id | doaj-art-ffe6abdbc18743488dc24b5761a8c37b |
| institution | DOAJ |
| issn | 1574-7891 1878-0261 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj-art-ffe6abdbc18743488dc24b5761a8c37b2025-08-20T02:43:43ZengWileyMolecular Oncology1574-78911878-02612025-07-011972056207310.1002/1878-0261.13741Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patientsNataša Stojanović Gužvić0Florian Lüke1Steffi Treitschke2Andrea Coluccio3Martin Hoffmann4Giancarlo Feliciello5Adithi Ravikumar Varadarajan6Xin Lu7Kathrin Weidele8Catherine Botteron9Silvia Materna–Reichelt10Felix Keil11Katja Evert12Florian Weber13Thomas Schamberger14Michael Althammer15Jirka Grosse16Dirk Hellwig17Christian Schulz18Stephan Seitz19Peter Ugocsai20Anke Schlenska‐Lange21Roman Mayr22Ulrich Kaiser23Wolfgang Dietmaier24Bernhard Polzer25Jens Warfsmann26Kamran Honarnejad27Tobias Pukrop28Daniel Heudobler29Christoph A. Klein30Christian Werno31Fraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyExperimental Medicine and Therapy Research University of Regensburg GermanyExperimental Medicine and Therapy Research University of Regensburg GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyBavarian Cancer Research Center (BZKF) Regensburg GermanyDepartment of Oncology and Hematology Hospital Barmherzige Brüder Regensburg GermanyDepartment of Urology, Caritas St. Josef Medical Center University of Regensburg GermanyDepartment of Internal Medicine III University Hospital Regensburg GermanyInsitute for Pathology University of Regensburg GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyDepartment of Internal Medicine III University Hospital Regensburg GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyFraunhofer Institute for Toxicology and Experimental Medicine ITEM‐R GermanyWhile cell‐free liquid biopsy (cfLB) approaches provide simple and inexpensive disease monitoring, cell‐based liquid biopsy (cLB) may enable additional molecular genetic assessment of systemic disease heterogeneity and preclinical model development. We investigated 71 blood samples of 62 patients with various advanced cancer types and subjected enriched circulating tumor cells (CTCs) to organoid culture conditions. CTC‐derived tumoroid models were characterized by DNA/RNA sequencing and immunohistochemistry, as well as functional drug testing. Results were linked to molecular features of primary tumors, metastases, and CTCs; CTC enumeration was linked to disease progression. Of 52 samples with positive CTC counts (≥1) from eight different cancer types, only CTCs from two salivary gland cancer (SGC) patients formed tumoroid cultures (P = 0.0005). Longitudinal CTC enumeration of one SGC patient closely reflected disease progression during treatment and revealed metastatic relapse earlier than clinical imaging. Multiomics analysis and functional in vitro drug testing identified potential resistance mechanisms and drug vulnerabilities. We conclude that cLB might add a functional dimension (to the genetic approaches) in the personalized management of rare, difficult‐to‐treat cancers such as SGC.https://doi.org/10.1002/1878-0261.13741CTCliquid biopsypersonalized tumor therapysalivary gland cancertumoroid culture |
| spellingShingle | Nataša Stojanović Gužvić Florian Lüke Steffi Treitschke Andrea Coluccio Martin Hoffmann Giancarlo Feliciello Adithi Ravikumar Varadarajan Xin Lu Kathrin Weidele Catherine Botteron Silvia Materna–Reichelt Felix Keil Katja Evert Florian Weber Thomas Schamberger Michael Althammer Jirka Grosse Dirk Hellwig Christian Schulz Stephan Seitz Peter Ugocsai Anke Schlenska‐Lange Roman Mayr Ulrich Kaiser Wolfgang Dietmaier Bernhard Polzer Jens Warfsmann Kamran Honarnejad Tobias Pukrop Daniel Heudobler Christoph A. Klein Christian Werno Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients Molecular Oncology CTC liquid biopsy personalized tumor therapy salivary gland cancer tumoroid culture |
| title | Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients |
| title_full | Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients |
| title_fullStr | Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients |
| title_full_unstemmed | Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients |
| title_short | Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients |
| title_sort | cellular liquid biopsy provides unique chances for disease monitoring preclinical model generation and therapy adjustment in rare salivary gland cancer patients |
| topic | CTC liquid biopsy personalized tumor therapy salivary gland cancer tumoroid culture |
| url | https://doi.org/10.1002/1878-0261.13741 |
| work_keys_str_mv | AT natasastojanovicguzvic cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT florianluke cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT steffitreitschke cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT andreacoluccio cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT martinhoffmann cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT giancarlofeliciello cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT adithiravikumarvaradarajan cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT xinlu cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT kathrinweidele cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT catherinebotteron cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT silviamaternareichelt cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT felixkeil cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT katjaevert cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT florianweber cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT thomasschamberger cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT michaelalthammer cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT jirkagrosse cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT dirkhellwig cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT christianschulz cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT stephanseitz cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT peterugocsai cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT ankeschlenskalange cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT romanmayr cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT ulrichkaiser cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT wolfgangdietmaier cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT bernhardpolzer cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT jenswarfsmann cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT kamranhonarnejad cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT tobiaspukrop cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT danielheudobler cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT christophaklein cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients AT christianwerno cellularliquidbiopsyprovidesuniquechancesfordiseasemonitoringpreclinicalmodelgenerationandtherapyadjustmentinraresalivaryglandcancerpatients |